Takeda's zasocitinib outperforms deucravacitinib in Phase 3 psoriasis head-to-head
- Zasocitinib showed statistical superiority to deucravacitinib for the primary endpoint PASI 100 at week 16.
- More than 35% of zasocitinib-treated patients achieved PASI 100 at week 16, over 2.5 times the response rate for deucravacitinib.
- Study enrolled 606 participants; dosing was zasocitinib 30 mg once daily versus deucravacitinib 6 mg once daily, with a 16-week treatment period within a 25-week study.
- Safety was consistent with prior studies and no new safety signals were reported.
Topline results
In the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) randomized, multicenter, double-blind head-to-head trial, zasocitinib demonstrated statistical superiority to deucravacitinib for the primary endpoint (PASI 100 at week 16) and for all key secondary endpoints, including PASI 90 and sPGA 0 at week 16.
Efficacy
More than 35% of participants treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16, a rate described as more than 2.5 times that observed with deucravacitinib; separation from the deucravacitinib curve was seen as early as week 8.
Safety
Zasocitinib was generally well tolerated with a safety and tolerability profile consistent with previous studies, and no new safety signals were identified.
Study design and next steps
The trial enrolled 606 adults with moderate-to-severe plaque psoriasis who received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for a 16-week treatment period within a study lasting up to 25 weeks. Takeda intends to present detailed data at upcoming medical congresses and plans to submit a New Drug Application for plaque psoriasis starting this fiscal year.
Source: Takeda
